Reference

Last reviewed: 28 Apr 2026
Sources cited: 10

Compound class~4,813 Da

Modified GLP-1 / GIP dual agonist

39-residue peptide with C20 fatty-acid conjugate at Lys20 for albumin binding. Proprietary sequence adapted from GIP backbone. Once-weekly dosing.

Tirzepatide

Last verified: 2026-04-24

At a glance


Also known as	Mounjaro (UK/EU brand for type 2 diabetes and weight management), Zepbound (US brand for weight management), LY3298176
Class	Dual GLP-1 / GIP receptor agonist — the first of its class
Typical route	Subcutaneous injection, once weekly
UK status	MHRA-approved prescription-only medicine (POM). Available through NHS (restricted pathway) and private prescription.
Plasma half-life	~5 days (long; enables once-weekly dosing)
Duration of effect	Steady-state reached at 4 weeks; effects persist throughout the week
Molecular weight	~4,813 Da (39 amino acids)

What it is

Tirzepatide is a licensed pharmaceutical medicine, not a research chemical. In the UK it’s sold as Mounjaro (Eli Lilly) and is MHRA-approved for type 2 diabetes management and chronic weight management. This is a meaningfully different regulatory and safety picture from everything else in this encyclopedia.

It’s the first-in-class dual agonist — simultaneously activating both the GLP-1 receptor (the mechanism of semaglutide/Ozempic/Wegovy) and the GIP receptor. The dual mechanism produces greater weight loss effects than GLP-1 agonism alone, with the SURMOUNT-5 head-to-head trial showing 47% greater weight loss on tirzepatide vs semaglutide.

It’s the most-studied, most-regulated, best-evidenced compound in this encyclopedia — backed by the SURMOUNT (obesity) and SURPASS (diabetes) clinical trial programmes, funded by Eli Lilly, with tens of thousands of participants.

Mechanism

Tirzepatide’s mechanism is unusually well-mapped because it’s a licensed medicine with extensive regulatory scrutiny.

GLP-1 receptor activation. Reduces appetite, slows gastric emptying (so meals feel more filling), enhances glucose-dependent insulin secretion, suppresses glucagon release.
GIP receptor activation. Acts directly on adipose tissue to improve insulin sensitivity and preferentially reduce visceral fat. In animal models, GIP receptor agonism reduces food intake and improves energy expenditure.
Dual mechanism synergy. The combination produces meaningfully greater effects than either mechanism alone — on weight, on glucose control, and on cardiometabolic markers.
Long half-life. The ~5-day half-life enables once-weekly dosing, which is a significant quality-of-life advantage over daily GLP-1 agonists.

The dual GIP/GLP-1 agonism is the key innovation. GIP had historically been considered less therapeutically interesting than GLP-1; tirzepatide’s success has shifted that thinking. Retatrutide (which we cover separately) extends this further with triple agonism.

Routes of administration

Subcutaneous injection (prefilled pen — the licensed route)


Form	Mounjaro prefilled injection pens at 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Frequency	Once weekly, same day each week
Site rotation	Abdomen, thigh, or upper arm. Rotate sites.
Onset	Appetite suppression effects within days; significant weight loss over weeks to months
Equipment	Pen is self-contained — no reconstitution, no separate syringe, no BAC water. The pen auto-injects.

The licensed and standard route. Mounjaro pens are convenient: no reconstitution, no dose calculation, no syringe drawing — just select the dose week (per the titration schedule), apply to skin, press, hold. The UI is designed for self-injection by patients without pharmacy background.

This is a key difference from research-chemical peptides. Mounjaro users don’t need to know about bacteriostatic water or insulin syringes. The device handles the delivery details.

Compounded / grey-market tirzepatide

This is covered in detail under “Areas of concern.” Briefly: compounded tirzepatide exists, is sold through grey-market channels, and is unlicensed medicine under UK law.

Other routes

Tirzepatide is not available or effective orally, sublingually, intranasally, or topically. Subcutaneous injection via the licensed pen is the only viable route.

What the evidence says

Honest summary: this is the best-evidenced weight-loss intervention in modern medicine, full stop. The SURMOUNT and SURPASS trial programmes are the gold standard of modern pharmaceutical evidence.

SURMOUNT-1 (obesity, non-diabetic)

2,539 adults with obesity (BMI 30+, or 27+ with weight-related complications)
Phase 3, double-blind, placebo-controlled, 72 weeks
Weight loss at week 72:
5 mg: −15.0% (mean)
10 mg: −19.5%
15 mg: −20.9%
Placebo: −3.1%
50% (10 mg) and 57% (15 mg) of participants lost ≥20% of body weight vs 3% on placebo
Discontinuation due to adverse events: 2.6% (placebo) to 7.1% (10 mg)1

SURMOUNT-2, -3, -4 (extension and maintenance)

Demonstrated weight loss maintenance with continued treatment
Showed regain after discontinuation — a finding that matters clinically and commercially
Up to 26.6% mean weight loss achievable with continued tirzepatide following intensive lifestyle intervention2

SURMOUNT-5 (head-to-head with semaglutide)

Tirzepatide 20.2% weight loss vs semaglutide 13.7% — 47% greater weight loss for tirzepatide3

SURPASS programme (type 2 diabetes)

HbA1c reductions of 1.87% to 3.02% across trials
Up to ≥15% weight loss with HbA1c ≤6.5% achievable — outcomes previously unreachable with any diabetes medication

Cardiovascular outcomes

Ongoing SURPASS-CVOT trial examining major adverse cardiovascular events
GLP-1 agonists as a class have demonstrated cardiovascular benefit; tirzepatide is expected to show similar or greater benefit given its broader metabolic effects

Prediabetes reversal

In SURMOUNT-1, >95% of participants with prediabetes at baseline converted to normoglycemia on tirzepatide, vs 62% on placebo

The evidence tier is different

Unlike research-chemical peptides where we’ve documented individual small studies, tirzepatide has:

Multiple Phase 3 trials with thousands of participants each
Head-to-head comparisons with existing medications
Regulatory approval in multiple jurisdictions
Real-world evidence from millions of patient-months of use
Ongoing post-marketing surveillance

This doesn’t make tirzepatide universally the right choice — but it does mean the efficacy picture is clearly established in a way no other compound in this encyclopedia matches.

Typical use patterns

Unlike research chemicals where dosing is community-derived, tirzepatide dosing comes from the licensed prescribing information and is titrated for tolerability.

Standard titration schedule (from Mounjaro prescribing information)

Weeks	Dose
1–4	2.5 mg weekly (starting dose — therapeutic effect minimal; tolerance-building)
5–8	5 mg weekly (first maintenance dose — therapeutic)
9–12	7.5 mg if further escalation needed
13–16	10 mg (common target maintenance dose)
17–20	12.5 mg if response insufficient
21+	15 mg (maximum dose)

Each step is minimum 4 weeks at that dose before escalation. If GI side effects are troublesome at a new dose, remaining at the current dose for an additional 4 weeks before re-attempting is standard clinical practice.

Not everyone needs maximum dose

Many patients achieve good response at 5 mg, 7.5 mg, or 10 mg. Individualisation is the norm — the maximum 15 mg is for patients who need or tolerate it, not a universal target.

Timing

Same day each week
Any time of day; can be adjusted if needed (up to 4 days before/after scheduled day without missing a dose)
Before or after food is fine — not meal-dependent

Duration of treatment

For obesity: ongoing treatment is required to maintain weight loss. Discontinuation typically results in weight regain.
For type 2 diabetes: ongoing treatment as part of diabetes management, same principle
This is not a short-term intervention. Users should expect multi-year commitment if they want sustained results.

For sensitive systems

Tirzepatide’s “sensitive systems” considerations are different from most compounds here because the evidence base is clinical, the side effects are well-characterised, and the user population already includes many chronically-ill individuals.

Start approach. The standard 2.5 mg starting dose is already a “sensitive start” — the licensed titration is deliberately slow to build tolerance. Some specialists use an even slower titration (longer than 4 weeks at each step) for patients with heightened GI sensitivity.

Expected adjustment profile:

Nausea is the defining side effect. ~29% of users experience it, typically peaking 1–2 weeks after each new dose and fading. Usually mild-to-moderate; severe nausea is less common.
Vomiting in a minority of users, typically dose-dependent
Diarrhoea or constipation — both occur; constipation often more persistent
Reduced appetite — the point of the medication, but can feel odd
Fatigue for some users, particularly early
Injection site reactions — mild, transient
Reflux — can worsen in users with existing GERD

For MCAS / histamine-sensitive users:

Tirzepatide’s slow GI transit can exacerbate histamine issues in users with histamine intolerance (slowed emptying means more time for histamine-producing bacterial overgrowth)
Some MCAS users report tolerating tirzepatide well; others find GI effects aggravate their baseline
Starting at 2.5 mg and staying longer at each dose step is the main sensitive-systems strategy — slower titration, more tolerance building

For POTS / autonomic dysfunction users:

Tirzepatide can worsen dehydration (through nausea, vomiting, reduced intake)
Dehydration worsens POTS
Electrolyte repletion and deliberate fluid intake are especially important
Some specialists recommend even slower titration

For gastroparesis / severe GI motility issues:

Tirzepatide slows gastric emptying — if you already have delayed emptying, this effect is additive
May be contraindicated depending on severity; clinical decision

For PMDD users:

Weight and metabolic changes can interact with PMDD symptoms — both directions reported
Some users find PMDD improves (metabolic stability helps cyclical symptoms)
Others find worsening during early GI-side-effect period coinciding with luteal phase

For ME/CFS / chronic fatigue users:

Tirzepatide is not fatigue-friendly in the first weeks
If already at low energy baseline, the early fatigue and GI effects may be disabling
Starting very slowly and at very low weight-loss targets is more realistic than aggressive escalation

Interactions worth considering:

Insulin and sulphonylureas: increased hypoglycaemia risk. Often requires reducing doses of these medications when starting tirzepatide.
Other GLP-1 agonists: do not combine. Do not use alongside semaglutide, liraglutide, etc.
Oral medications: tirzepatide slows gastric emptying, which can affect absorption of other oral medications. Oral contraceptives — efficacy may be reduced; alternative contraception or barrier methods recommended for at least 4 weeks after each dose escalation.
Warfarin, diabetes medications: INR or blood glucose monitoring may need adjustment
Research-chemical peptides: no documented interactions with BPC-157, Semax, etc. But combining prescription medicine with research chemicals is not studied and is probably best discussed with prescribing clinician.
LDN: no documented interaction; commonly used together
SSRIs/SNRIs: no documented interaction; commonly used together

Reasonable expectations

Onset. Appetite suppression within days of first dose. Subjectively “feeling different” about food in 1–2 weeks. Measurable weight loss starting weeks 4–8. Significant weight loss at weeks 20–40. Full effect at 72 weeks of treatment.

Response rate. >80% of users achieve meaningful weight loss (≥5% body weight) on tirzepatide in clinical trials. About half achieve ≥20% weight loss. This is dramatically higher response than any previous weight-loss medication.

What the evidence actually supports.

15–21% mean body weight reduction over 72 weeks — well-established
Prediabetes reversal — well-established
HbA1c reduction for type 2 diabetes — well-established; superior to most other diabetes medications
Cardiovascular benefit — expected based on class effect; confirmatory trial ongoing
Weight maintenance with continued treatment — established
Weight regain on discontinuation — established; this is a long-term treatment

What not to expect.

Permanent weight loss from a short course. This is a chronic-treatment medication; stopping typically reverses effects.
Effortless body composition change. Tirzepatide reduces appetite and improves metabolism; it does not build muscle, improve fitness, or replace exercise.
Protection against age-related metabolic decline without treatment continuation
A substitute for dietary and lifestyle changes if you want optimal outcomes — the trials combined tirzepatide with lifestyle intervention
Miraculous results at low doses. Effect is dose-dependent up to 15 mg; going higher doesn’t continue the pattern and isn’t supported

Cost

Private prescription — the most common UK access route

Dose / provider	Typical monthly cost
2.5 mg (starter)	£124–180
5 mg	£150–220
7.5 mg	£170–250
10 mg	£180–280
12.5 mg	£200–300
15 mg	£220–375

Major UK providers (all GPhC-registered, MHRA-authorised):

Superdrug Online Doctor
Boots Online Doctor
Asda Online Doctor
Numan
Voy (formerly Manual)
LloydsPharmacy Online Doctor
Medino
Bolt Pharmacy
The Family Chemist

NHS access

Very restricted. Available through Tier 3 specialist weight management services.
Eligibility criteria: typically BMI ≥35 with weight-related comorbidity, or ≥40 without, and previous engagement with weight management programmes.
NHS prescription charge: £9.90 per item in England (2026); free in Scotland, Wales, Northern Ireland.
Most UK users access tirzepatide privately due to NHS restrictions and waiting lists.

Provider comparison matters

Pricing varies significantly between providers — sometimes £50–100/month difference for the same dose. Consultation quality, clinical review thoroughness, and ongoing support vary too. “Cheapest provider” is not the same as “best provider.”

Reasonable provider-selection criteria:

GPhC registration — verifiable on the General Pharmaceutical Council register
MHRA authorisation — provider should be licensed for online pharmacy services
Proper clinical review — legitimate providers require medical questionnaire, often video/photo verification, and ongoing check-ins
Clear sourcing — licensed tirzepatide should be sourced through standard pharmaceutical distribution, not compounded
Ongoing support — side effect management, dose titration guidance, nutritional support

Red flags suggesting illegitimate provider: no medical review, cash-only payment, extremely low pricing, vague sourcing, no UK address.

Reconstitution

This section covers reconstitution of research-chemical tirzepatide. Mounjaro and Zepbound arrive as prefilled pens and require no preparation — if that’s your route, skip this section. Like semaglutide, tirzepatide has a real licensed pen pathway in the UK, so reconstitution is for the cohort buying lyophilised powder from research-chem vendors, typically because of cost, supply gaps, or specific dosing patterns the licensed pens can’t deliver.

What’s in the box

Research-chemical tirzepatide ships as lyophilised white powder in a glass vial, typically 5 mg, 10 mg, or 15 mg per vial. 15 mg vials are stocked more widely than for semaglutide because tirzepatide’s licensed dose ceiling (15 mg/week) is higher and full-titration users go through a vial faster. The vial is sealed with a rubber stopper and aluminium crimp.

You’ll also need:

Bacteriostatic water (BAC water) — sterile water with 0.9% benzyl alcohol. Required for the standard 28-day stability window.
Insulin syringe (U-100) — typically 1 mL with 29G–31G needle. 100 units = 1 mL, so each unit = 0.01 mL.
A larger syringe (3 mL or 5 mL) for transferring BAC water into the vial.
Alcohol wipes, a clean working surface, and somewhere to record what you did.

The three practitioner camps

Tirzepatide users split into three patterns. The picture sits between semaglutide and retatrutide: licensed pens are widely available (like sema) but the dose-response curve is steeper for weight loss (closer to reta), so the camps cluster slightly differently in practice.

The standard titration camp follows the Mounjaro/Zepbound schedule: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg/week, escalating every 4 weeks. One injection per week. This is the camp the trial data and licensed prescribing schedule were designed for. Research-chem users typically buy 10 mg or 15 mg vials and follow the same dose ladder.

The split-dosing camp takes the same total weekly dose and divides it into two injections, typically Monday and Thursday. The community sometimes calls this “microdosing,” which is a misnomer: real microdosing means an order of magnitude below the therapeutic range, and split dosing keeps the total weekly dose unchanged. Only the per-injection peak is smaller.

The pharmacological case for split dosing is slightly stronger for tirzepatide than for semaglutide: tirzepatide’s plasma half-life is ~5 days, shorter than the 7-day dose interval, so by injection day only ~38% of last week’s dose is still circulating (versus ~50% for semaglutide). That means slightly bigger weekly peak-to-trough swings on tirzepatide. However, tirzepatide’s GIP arm appears to buffer GI side effects compared to pure GLP-1 agonism, so the felt benefit of split dosing is often smaller than the PK math would suggest. Many tirzepatide users tolerate once-weekly fine; split dosing is more common for users escalating to 12.5 or 15 mg, or those who didn’t tolerate semaglutide.

The sustained-low-dose camp runs absolute weekly doses below the 2.5 mg titration floor — typically 1–2.5 mg/week — held flat over a cycle rather than escalated. The goals are similar to the sema low-dose camp: milder side effects, lower per-month cost, slower sustained weight loss. The dose-response curve for tirzepatide is steep enough that even 1 mg/week produces noticeable appetite effects in many users; this camp is smaller in absolute numbers than for semaglutide but better-justified pharmacologically because the floor of effect is lower than the licensed starting dose. This is also sometimes called “microdosing” in the community, but it’s the low end of normal tirzepatide dosing rather than a true microdose.

All three patterns are real and used widely. None is “wrong” — they’re different goals. The reconstitution math just needs to match the goal.

The math

For research-chem reconstitution, the rule is: pick a BAC volume that puts each injection at a syringe mark you can read accurately. U-100 insulin syringe markings get hard to read below ~5 units (0.05 mL), so aim higher than that for accuracy. Tirzepatide’s per-injection doses sit between semaglutide’s (~0.25–2.4 mg) and retatrutide’s (~2–12 mg) in absolute size, so the math is the most syringe-friendly of the three.

Standard titration — 10 mg vial, 2 mL BAC water (the most commonly cited setup)

Concentration: 5 mg/mL (5,000 mcg/mL)
2.5 mg weekly = 0.5 mL = 50 units
5 mg weekly = 1 mL = 100 units (the full readable range of a 1 mL insulin syringe)
7.5 mg weekly = 1.5 mL = 150 units (over a single 100-unit syringe — split into two injections, or use a 3 mL syringe, or reconstitute denser)
10 mg weekly = 2 mL = the whole vial. Reconstitute denser for weekly doses ≥7.5 mg.

Standard titration at higher doses — 15 mg vial, 1.5 mL BAC water

Concentration: 10 mg/mL
5 mg weekly = 0.5 mL = 50 units
7.5 mg weekly = 0.75 mL = 75 units
10 mg weekly = 1 mL = 100 units (full single-syringe range)
12.5 mg weekly = 1.25 mL = 125 units (over the 100-unit mark; consider a slightly denser reconstitution or a 3 mL syringe)
15 mg weekly = 1.5 mL = 150 units (over the 100-unit mark)

Split dosing — 10 mg vial, 2 mL BAC water

Same 5 mg/mL concentration; the math is per-injection.
5 mg/week as 2.5 mg twice weekly = 0.5 mL = 50 units, twice weekly
10 mg/week as 5 mg twice weekly = 1 mL = 100 units, twice weekly
15 mg/week as 7.5 mg twice weekly = 1.5 mL = 150 units twice weekly (over the 100-unit mark; use denser reconstitution or a 3 mL syringe)

Sustained low dose — 5 mg vial, 2.5 mL BAC water

Concentration: 2 mg/mL (2,000 mcg/mL)
1 mg weekly = 0.5 mL = 50 units
1.5 mg weekly = 0.75 mL = 75 units
2 mg weekly = 1 mL = 100 units

The Peptrax Vial Plan calculator handles the same math interactively — enter your vial size, BAC volume, and weekly dose, and it returns draw volume, doses per vial, and depletion timing.

Reconstitution procedure

Wipe the rubber stopper of the lyophilised vial and the BAC water vial with alcohol.
Draw the chosen volume of BAC water into the larger syringe.
Insert the needle into the lyophilised vial at an angle, with the tip touching the inside wall of the vial above the powder. Inject the water slowly down the inside of the vial, not directly onto the powder. Forcing water onto lyophilised peptide can denature it.
Leave the vial undisturbed for 1–2 minutes. Do not shake. Gently swirl if needed; the powder will dissolve on its own. Shaking creates foam and can fragment peptide chains.
Once the solution is clear, label the vial: compound, concentration, reconstitution date.
Store refrigerated (2–8°C / 36–46°F).

Some practitioners pass the reconstituted solution through a 0.22 µm syringe filter as a belt-and-braces sterility step. With a sealed lyophilised vial and clean technique, this is optional rather than standard — the vial was sterile when sealed, and your BAC water contains benzyl alcohol. Filtering is more relevant if you’re concerned about a specific vendor’s lyophilisation quality or if you’re using plain (non-bacteriostatic) sterile water for a single-use prep.

Storage and stability

Tirzepatide reconstituted with BAC water has stability data in roughly the same range as semaglutide, with both informed by Eli Lilly’s pen specs and US compounding-pharmacy guidance:

Conservative: 21 days refrigerated. Some compounding pharmacies and research-supply vendors give this as the safe window; matches the Mounjaro pen’s 21-day in-use shelf life at refrigerated temperatures.
Middle: 28 days refrigerated. The most commonly cited figure across community sources and peptide vendors. Tracks with US compounding-pharmacy beyond-use dates of 28 days.
Optimistic: 30–90 days refrigerated. US compounding pharmacies sometimes assign beyond-use dates up to 90 days based on USP guidelines for specific formulations; this depends on the formulation, sterility verification, and storage conditions, none of which apply to a typical grey-market reconstitution.

The honest middle is 28 days refrigerated at 2–8°C. This is the figure the licensed Mounjaro pen uses post-opening (give or take a week), and the figure most commonly quoted for self-reconstituted research-chem tirzepatide.

Store at the back of the refrigerator where the temperature is most stable, not in the door. Do not freeze — ice crystal formation disrupts peptide structure and reduces potency on thaw.

If you reconstitute with plain sterile water instead of BAC water, the vial is single-use — discard within 24 hours because there’s no preservative.

The stability constraint hits each camp differently. A 10 mg vial dosed at 5 mg/week is 2 weeks of doses — well within shelf life. A 15 mg vial at full 15 mg/week is one week per vial — no constraint at all. The split-dosing camp at 5 mg twice-weekly is also one week per 10 mg vial. The sustained-low-dose camp at 1 mg/week from a 5 mg vial is 5 weeks of theoretical doses but only ~4 weeks of stable solution — small loss, manageable.

What gets miscalculated

The recurring grey-market reconstitution errors for tirzepatide, in rough order of frequency:

Confusing mg, mcg, and units. 1 mg = 1,000 mcg. A “10-unit” dose on a U-100 syringe is 0.1 mL of solution, not 10 mcg of compound. Tirzepatide’s per-injection doses are large enough that the mg/mcg trap is less common than for semaglutide, but the mg/units confusion still happens.
Reading “units” as mg. “Take 50 units” is not “take 50 mg.” Units are a volume mark on the syringe.
Using Mounjaro/Zepbound pen dose conversions with research-chem vials without doing the reconstitution math first. The pen delivers a fixed mg per click; the powder needs to be reconstituted to a chosen concentration first.
Higher doses overrunning the 100-unit syringe. At the standard 5 mg/mL concentration, anything ≥7.5 mg/week needs splitting across multiple draws or a denser reconstitution. This catches users titrating to 10–15 mg without thinking through the syringe limit.
Underestimating shelf life loss at low doses. Sustained-low-dose users running 1 mg/week from a 5 mg vial discard a small fraction of the vial; users tempted to buy 15 mg vials at low doses for a “bulk discount” lose much more.

Areas of concern ⚠

Compounded and grey-market tirzepatide (the major UK concern)

Compounded tirzepatide is unlicensed medicine under UK law.

The situation:

During the 2024–2025 global GLP-1 shortage, some US compounding pharmacies produced tirzepatide at lower cost than branded Mounjaro
Some of this supply entered the UK grey market through unregulated channels
In October 2025, UK MHRA dismantled an illicit drug factory in Northampton producing unlicensed tirzepatide and retatrutide pens
Eli Lilly has warned of chemical impurities in compounded tirzepatide

Why this matters:

Quality is not guaranteed. Bacterial contamination, endotoxin elevation, and incorrect dosing have been documented in grey-market samples
Legal exposure: selling unlicensed tirzepatide is a criminal offence in the UK. Buying and using it is technically unlawful under the Human Medicines Regulations 2012, though end-user prosecution is rare.
No medical oversight. Compounded suppliers do not typically require medical consultation, do not screen for contraindications (MTC history, pancreatitis, etc.), and do not provide ongoing clinical care
Counterfeit risk: some “compounded tirzepatide” is not actually tirzepatide. Chemical analysis has found underpotent, impure, or incorrectly-labelled product.

If cost is a barrier, the practical comparison is between regulated UK providers rather than grey-market supply. Price variation between licensed providers is often larger than readers expect.

Gallbladder and biliary disease (established concern)

Meta-analysis showed significantly increased risk of gallbladder/biliary events (RR 1.97 vs placebo)
Partly due to rapid weight loss (which independently increases gallstone risk), partly a direct medication effect
Not a contraindication in absence of existing gallbladder disease, but worth monitoring for right-upper-quadrant pain, especially at higher doses

Pancreatitis (smaller concern than sometimes claimed)

Meta-analysis of 9 trials (9,871 participants) found no statistically significant increase in pancreatitis risk
However: history of pancreatitis is a reason for caution; acute pancreatitis symptoms during treatment require immediate cessation and medical evaluation
Presentation: persistent severe abdominal pain, often radiating to back, with or without vomiting

Thyroid tumour concern (rodent finding)

Animal studies: tirzepatide caused thyroid C-cell tumours in rodents
Not observed in human trials to date
Calcitonin levels have remained stable in tirzepatide human studies
Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Rapid weight loss complications

Gallstones (as above)
Muscle mass loss if insufficient protein intake and resistance exercise — probably the single biggest under-discussed issue
Nutritional deficiencies with dramatically reduced food intake
“Ozempic face” / volume loss: rapid subcutaneous fat loss affects facial appearance; proportional to weight loss magnitude
Loose skin with significant weight loss

Long-term safety

Clinical trial data extends to ~2 years
Real-world use now approaching 4 years since first approvals
Long-term (10+ year) safety not yet characterised — but the GLP-1 class has 15+ years of use with reassuring aggregate safety
Ongoing post-marketing surveillance through MHRA Yellow Card scheme (UK) and FDA MedWatch (US)

Populations where tirzepatide is contraindicated or requires extra caution

Personal or family history of medullary thyroid carcinoma (MTC) — contraindicated
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — contraindicated
Pregnancy — contraindicated; effective contraception required. Discontinue ≥2 months before planned conception.
Severe gastroparesis — relative contraindication
History of pancreatitis — use with caution; specialist input
Type 1 diabetes — not licensed for T1DM; use only under specialist supervision if combined with insulin
Severe kidney or liver impairment — specialist input required
Under 18 — not licensed for paediatric use in UK

The dependency question

Tirzepatide works as long as you take it. Weight regain after discontinuation is the norm, not the exception. This frames the medication as chronic disease management (like antihypertensives) rather than a time-limited intervention. Reasonable people disagree on whether this is a feature (treating obesity as a chronic disease) or a concern (lifetime dependence on pharmaceutical intervention). It’s a real choice to make before starting.

FDA / regulatory status

Jurisdiction	Status	Last verified
UK (MHRA)	MHRA-approved as Mounjaro for type 2 diabetes and chronic weight management. Prescription-only medicine (POM).	2026-04-24
US (FDA)	FDA-approved as Mounjaro (T2DM, 2022) and Zepbound (obesity, 2023). Prescription-only.	2026-04-24
EU (EMA)	EMA-approved as Mounjaro. Prescription-only.	2026-04-24
NHS England	Available through restricted Tier 3 specialist weight management services (rollout ongoing)	2026-04-24
NHS Scotland, Wales, NI	Availability varies by region; generally more restricted than private prescription	2026-04-24
WADA (sport)	Not on prohibited list. Used medically; not performance-enhancing in the traditional sport-testing sense.	2026-04-24

Narrative. Tirzepatide is a licensed medicine in the UK. Most UK users access it through private prescription from regulated online pharmacies — this is a legal, appropriate, and well-regulated pathway. The grey-market compounded supply is a separate and concerning issue, but does not need to enter the picture for legitimate UK access.

For UK readers: tirzepatide is legal to obtain and use via prescription from UK-licensed providers. Compounded or grey-market tirzepatide remains unlicensed medicine under UK law.

What to track in Peptrax

Tirzepatide is the compound where structured tracking has the clearest clinical value, because the dose-titration schedule is real and the GI side-effect profile follows it predictably. Weekly weight, weekly waist if you measure it, GI symptoms (nausea, reflux, constipation, diarrhoea) on a 0–5 scale, and appetite/cravings notes are the core. Most people are on a 4-week-per-dose escalation through 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, and pattern-matching side effects to dose changes is the most useful retrospective the app can support.

Realistically, almost everyone starting tirzepatide in the UK is on a private prescription — Numan, Voy, Boots Online, Superdrug Online Doctor, Lloyds Direct, or a similar licensed pathway — not NHS. Logging the prescriber, monthly cost, and dose schedule lets the cost-vs-effect conversation be honest at month 6: how much weight has actually moved, against how much you’ve spent, against how the side effects have settled. A clinician-facing summary at quarterly review is more useful with three months of structured data than with reconstructed memory.

The clinical-ish part of the register matters here. Track injection site rotation, missed-dose recovery (skip vs catch up depends on how many days late), and any concerning symptoms that warrant a prescriber conversation — persistent severe nausea, signs of pancreatitis (severe upper abdominal pain), gallbladder symptoms, hypoglycaemia if you’re on other diabetes medication. The app’s job here is to surface those as flags, not to replace the prescriber relationship.

For personal tracking and informational purposes only — not medical advice.